OncoCyte Corp (OCX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
OncoCyte Corp (NYSE:OCX) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.01, Bloomberg Earnings reports.
Shares of OncoCyte Corp (NYSE:OCX) traded up 2.02% during midday trading on Tuesday, hitting $5.05. 21,589 shares of the stock traded hands. OncoCyte Corp has a 52 week low of $3.40 and a 52 week high of $7.95. The firm has a 50-day moving average price of $4.67 and a 200-day moving average price of $5.39. The stock’s market capitalization is $148.31 million.
Several equities research analysts have recently issued reports on OCX shares. Zacks Investment Research raised shares of OncoCyte Corp from a “sell” rating to a “hold” rating in a research report on Wednesday, May 3rd. Chardan Capital reissued a “buy” rating and set a $7.75 price objective (up previously from $6.50) on shares of OncoCyte Corp in a research report on Tuesday, May 23rd.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp bought a new position in OncoCyte Corp during the second quarter worth about $211,000. Vanguard Group Inc. increased its position in OncoCyte Corp by 11.1% in the second quarter. Vanguard Group Inc. now owns 108,670 shares of the company’s stock worth $565,000 after buying an additional 10,892 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in OncoCyte Corp by 14.3% in the second quarter. Goldman Sachs Group Inc. now owns 42,015 shares of the company’s stock worth $218,000 after buying an additional 5,265 shares during the last quarter.
About OncoCyte Corp
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.